Random acceleration is a fundamental stochastic process encountered in many applications. In the one-dimensional version of the process a particle is randomly accelerated according to the Langevin equation x[over ̈](t)=sqrt[2D]ξ(t), where x(t) is the particle's coordinate, ξ(t) is Gaussian white noise with zero mean, and D is the particle velocity diffusion constant. Here, we evaluate the A→0 tail of the distribution P_{n}(A|L) of the functional I[x(t)]=∫_{0}^{T}x^{n}(t)dt=A, where T is the first-passage time of the particle from a specified point x=L to the origin, and n≥0. We employ the optimal fluctuation method akin to geometrical optics. Its crucial element is determination of the optimal path-the most probable realization of the random acceleration process x(t), conditioned on specified A, n, and L. The optimal path dominates the A→0 tail of P_{n}(A|L). We show that this tail has a universal essential singularity, P_{n}(A→0|L)∼exp(-α_{n}L^{3n+2}/DA^{3}), where α_{n} is an n-dependent number which we calculate analytically for n=0, 1, and 2 and numerically for other n. For n=0 our result agrees with the asymptotic of the previously found first-passage time distribution.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1103/PhysRevE.107.064122 | DOI Listing |
J Urban Health
January 2025
Department of Environmental Medicine and Climate Science, Icahn School of Medicine at Mount Sinai, 1 Gustave L. Levy Place, Box 1057, New York, NY, 10029, USA.
Chronological age is not an accurate predictor of morbidity and mortality risk, as individuals' aging processes are diverse. Phenotypic age acceleration (PhenoAgeAccel) is a validated biological age measure incorporating chronological age and biomarkers from blood samples commonly used in clinical practice that can better reflect aging-related morbidity and mortality risk. The heterogeneity of age-related decline is not random, as environmental exposures can promote or impede healthy aging.
View Article and Find Full Text PDFEur J Sport Sci
February 2025
School of Human Sciences (Exercise and Sport Science), The University of Western Australia, Perth, Australia.
End-range movements are among the most demanding but least understood in the sport of tennis. Using male Hawk-Eye data from match-play during the 2021-2023 Australian Open tournaments, we evaluated the speed, deceleration, acceleration, and shot quality characteristics of these types of movement in men's Grand Slam tennis. Lateral end-range movements that incorporated a change of direction (CoD) were identified for analysis using k-means (end-range) and random forest (CoD) machine learning models.
View Article and Find Full Text PDFStrahlenther Onkol
January 2025
Department of Radiation Oncology, Radboud university medical center, Nijmegen, The Netherlands.
Purpose: This study focused on reducing the margin for prostate cancer treatment using magnetic resonance imaging-guided radiotherapy by investigating the intrafractional motion of the prostate and different motion-mitigation strategies.
Methods: We retrospectively analyzed intrafractional prostate motion in 77 patients with low- to intermediate-risk prostate cancer treated with five fractions of 7.25 Gy on a 1.
Invest Ophthalmol Vis Sci
January 2025
NIHR Biomedical Research Centre, Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology, London, United Kingdom.
Purpose: To investigate the effect of average intraocular pressure (IOP) on the true rate of glaucoma progression (RoP) in the United Kingdom Glaucoma Treatment Study (UKGTS).
Methods: UKGTS participants were randomized to placebo or Latanoprost drops and monitored for up to two years with visual field tests (VF, 24-2 SITA standard), IOP measurements, and optic nerve imaging. We included eyes with at least three structural or functional assessments (VF with <15% false-positive errors).
Ther Adv Rare Dis
January 2025
SynGAP Research Fund, 2856 Curie Pl., San Diego, CA 92122, USA.
-related disorder (SRD) is a developmental and epileptic encephalopathy caused by a disruption of the gene. At the beginning of 2024, it is one of many rare monogenic brain disorders without disease-modifying treatments, but that is changing. This article chronicles the last 5 years, beginning when treatments for SRD were not publicly in development, to the start of 2024 when many SRD-specific treatments are advancing.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!